Neogen (NEOG) Q3 2026 earnings review
Cost Cuts Drive Margins Amid Segment Divergence
Neogen's turnaround under CEO Mike Nassif is taking a financially pragmatic shape, but operational fractures remain evident. In Q3, total revenue decelerated to a 4.4% YoY decline, dragged down by a severe 20% collapse in the Animal Safety segment due to supplier issues. However, the Food Safety core business showed accelerating growth (+4.0%), and aggressive cost-cutting expanded Adjusted EBITDA margin to 22.8%. The standout strategic move is the announced divestiture of the Genomics business to Zoetis for $160 million, which will materially deleverage the balance sheet. Management raised the FY26 revenue floor but held the EBITDA target flat at ~$175 million, implying a likely margin deceleration in Q4. Investors are buying the portfolio simplification, but supply chain execution remains a clear vulnerability.
🐂 Bull Case
Selling the Genomics business to Zoetis for $160M ($140M net) directly addresses the company's bloated balance sheet. Targeting a net debt-to-adjusted EBITDA ratio of less than 3x by year-end removes a major overhang.
The Food Safety segment is reversing its prior stagnation, posting 4.0% core growth. A standout 11% YoY jump in Indicator Testing & Culture Media validates the underlying demand for Neogen's primary franchise.
🐻 Bear Case
The Animal Safety segment reported a shocking 20.1% YoY revenue decline. Management cited third-party supplier setbacks. This signals acute vulnerability in domestic supply chain management.
While Adjusted EBITDA margins look stellar, GAAP gross margin actually collapsed from 49.9% to 46.9%. Duplicate manufacturing costs for Petrifilm and inventory write-offs are eating real cash.
⚖️ Verdict: ⚪
Neutral. The strategic moves (Genomics sale, cost cuts) are exactly what the doctor ordered to fix the balance sheet. However, a 20% drop in Animal Safety due to supplier issues proves operational execution is still highly unstable.
Key Themes
Genomics Divestiture Cleans the Slate
Neogen struck a definitive agreement to sell its global Genomics business to Zoetis for $160M. This is a massive positive driver. It offloads a segment that has historically been a volatile drag on growth, generating $140M in net proceeds to aggressively pay down debt. Management expects net leverage to drop below 3x by the end of CY2026.
Food Safety Core Re-accelerating
Food Safety, representing 74% of total revenue, is showing a stable recovery path. Core growth accelerated to 4.0% in Q3, up from a 1.7% decline in Q1. Indicator Testing & Culture Media led the charge, soaring 11.0% YoY to $83.0M. The go-to-market overhaul appears to be yielding tangible volume improvements in this critical segment.
Animal Safety Revenue Collapse
A severe operational break occurred in Animal Safety, where revenue reversed direction, plummeting 20.1% YoY to $54.5M (core growth -8.7%). Management explicitly blamed 'third-party, supply-based setbacks.' The Biosecurity sub-segment was hit hardest, crashing 37.0%. Supply chain fragility remains a glaring risk to top-line stability.
GAAP vs Non-GAAP Profitability Divergence
Management touted an Adjusted EBITDA margin expansion to 22.8% (up 110 bps sequentially). However, this contradicts the actual GAAP gross margin, which decelerated significantly from 49.9% a year ago to 46.9%. The 300 bps gross margin compression was driven by duplicate Petrifilm manufacturing costs, tariffs, and inventory write-offs—real costs that are conveniently excluded from Adjusted metrics.
Petrifilm Transition Execution Risk
The transfer of the complex Petrifilm technology to in-house manufacturing remains a critical operational hurdle. Management stated they are initiating operational and performance validation on multiple single kit units (SKUs). While 'on track' for November 2026 completion, the ongoing duplicate costs weighing on gross margin indicate this transition is an expensive, high-stakes tightrope walk.
Macro Geographic Divide: U.S. Weakness vs International Strength
A clear geographic divergence is stable: International revenue grew 3.1% YoY to $108.9M, driven by Europe and Latin America. In stark contrast, Domestic revenue shrank 11.4% to $102.3M. Management noted that the U.S. decline was heavily exacerbated by the Animal Safety supplier issues, as those product sales are predominantly domestic.
Other KPIs
Generated $22.7M in Q3, leading to free cash flow of $11.1M. While positive, the nine-month year-to-date OCF is $53.0M, only slightly up from $41.8M a year ago. Inventory levels remain elevated at $161.7M, indicating working capital improvements have stalled.
Total operating expenses decelerated, dropping 2.5% YoY from $104.9M. Sales and marketing specifically fell 14.3% YoY to $38.2M. This proves the ~10% headcount reduction and cost-saving initiatives announced by the new CEO in Q1 are flowing through to the bottom line.
Guidance
Accelerating slightly at the floor. Raised from previous $845-$855M. Given 9-month YTD revenue of $645.1M, the midpoint ($858.5M) implies Q4 revenue of roughly $213.4M, representing a sequential uptick from Q3's $211.2M, but assuming ongoing weakness in Animal Safety.
Stable. The company maintained this guidance despite raising revenue. With 9-month YTD Adjusted EBITDA at $132.4M, this implies Q4 Adjusted EBITDA of roughly $42.6M. This represents a significant sequential deceleration from Q3's $48.2M, indicating management expects margin compression or increased transition costs in Q4.
Key Questions
Animal Safety Supply Chain Depth
Revenue in Animal Safety collapsed 20% due to third-party supplier setbacks. What specific products were impacted, have the underlying supply contracts been secured, and when do you expect this segment to return to historical run-rates?
Implied Q4 Margin Deceleration
You raised the full-year revenue guide but held Adjusted EBITDA at $175 million. This implies a substantial sequential drop in Q4 Adjusted EBITDA to around $42 million. What specific headwinds or sequential cost increases are driving this expected margin compression?
Petrifilm Duplicate Costs Timeline
GAAP gross margins fell 300 basis points partly due to duplicate Petrifilm manufacturing costs. Will these duplicate costs peak in Q4, or should investors expect them to remain elevated until the final transition in November 2026?
Inventory Write-off Exposure
You cited inventory write-offs as a drag on Q3 gross margin. With inventories still sitting at $161.7M, are you comfortable with the current aging profile, or should we expect further write-offs as the SNOP process matures?